Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1 R132H , a structural alteration that leads to catalysis of a-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1 R132H that are being developed for cancer therapy may pose risks with coadministration of radiotherapy. Cancer cells heterozygous for the IDH1 R132H mutation exhibited less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there were higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects were reversed by the IDH1 R132H inhibitor AGI-5198. Exposure of IDH1 wild-type cells to D-2-hydroxyglutarate was sufficient to reduce IDH-mediated NADPH production and increase IR sensitivity. Mechanistic investigations revealed that the radiosensitivity of heterozygous cells was independent of the well-described DNA hypermethylation phenotype in IDH1-mutated cancers. Thus, our results argue that altered oxidative stress responses are a plausible mechanism to understand the radiosensitivity of IDH1-mutated cancer cells. Further, they offer an explanation for the relatively longer survival of patients with IDH1-mutated tumors, and they imply that administration of IDH1 R132H inhibitors in these patients may limit irradiation efficacy in this setting. Cancer Res; 75(22); 1-13. Ó2015 AACR.
Introduction
IDH1 and lDH2 are homodimeric enzymes that reversibly convert isocitrate to a-ketoglutarate (aKG) with concomitant reduction of NADP þ to NADPH in the cytoplasm and mitochondria, respectively (1) . Somatic heterozygous hotspot mutations in IDH1/2 (IDH MT ) are observed in substantial percentages of various tumor types, such as glioma (80%), acute myeloid leukemia (AML, 20%), cholangiocarcinoma (20%), chondrosarcoma (60%), and others (1) .
IDH MT cause metabolic changes in cancer (2) . All IDH MT , of which IDH1
R132H is the most prevalent in glioma, cause loss of enzymatic wild-type IDH (IDH WT ) function (3) (4) (5) . In addition, IDH MT have a neo-enzymatic (gain of function) activity: it converts aKG and NADPH to D-2-hydroxyglutarate (D-2HG) and NADP þ . D-2HG is an oncometabolite that is present in trace amounts in IDH WT cells but accumulates to levels up to 50 mmol/L in IDH MT cancers (6) . Because of the chemical similarities between D-2HG and aKG, D-2HG competitively inhibits aKGdependent dioxygenases, such as ten-eleven translocation factor 2 (TET2) and JmjC-domain containing histone lysine demethylases (JHKDM; refs. 7, 8) . This results in a CpG island methylation phenotype (CIMP), which alters gene expression and induces malignant transformation (9) .
Patients with IDH MT glioma and cholangiocarcinoma have up to 3-fold longer median overall survival times than IDH WT counterparts (3, 5, (10) (11) (12) . Altered patient survival caused by differences in IDH1
MT versus IDH1 WT tumor biology may be on the level of intrinsically reduced malignancy, and/or altered responses to therapy. We previously showed in human glioblastoma samples that IDH1
MT are associated with a 38% decrease in IDHmediated NADPH production capacity (5) . NADPH is the most important source of reducing power for cellular detoxification of oxidants, because it is an essential cofactor for the regeneration of reduced glutathione (GSH) from oxidized glutathione (GSSG) by glutathione reductase. Therefore, we and others proposed that altered redox responses result in increased responses to therapy in
IDH1
MT cancers (1, (13) (14) (15) . This hypothesis is supported by in vitro studies, showing that overexpression of IDH1 R132H sensitizes glioma cells to ionizing radiation (IR) or chemotherapy with carmustine (BCNU), cis-diaminedichloroplatinum (CDDP), or temozolomide (15) (16) (17) . In addition, there is clinical evidence that IDH1
MT sensitize glioma to a procarbazine, lomustine (CCNU), and vincristine (PCV) regimen (18) and sensitize glioblastoma to a combination of IR and temozolomide (19) .
IDH MT are early events in the formation of glioma (20) , chondrosarcoma (21) , and cholangiocarcinoma (22) , which makes IDH MT attractive therapeutic targets. Inhibitors of IDH1 MT and IDH2 MT were recently developed (23) (24) (25) (26) (27) . Clinical trials of the IDH1 R132H inhibitor AGI-5198 (ClinicalTrials.gov NCT02073994) are in progress in solid tumors. AGI-5198 inhibits IDH1
R132H neoenzymatic activity, which decreases D-2HG production in IDH1 MT cells, and thus inhibits carcinogenesis (23) . However, better prognosis of patients with established IDH MT glioma or cholangiocarcinoma (which are past the carcinogenesis stage) may be related to increased anticancer therapy responses by virtue of increased oxidative stress in these tumors due to a lower NADPH production capacity. Thus, we argued that inhibition of IDH MT decreases this stress and consequently increases cancer cell survival (1, 2) .
The aim of the present study is to provide in vitro evidence that the prolonged overall survival of glioma patients with IDH1 MT tumors is caused by increases in oxidative stress, and in particular, reduced NADPH production capacity. We investigated whether this stress affects the response to IR and metformin. Moreover, we studied whether the IDH1 R132H inhibitor AGI-5198 blocks this metabolic stress, thus interfering with the survival-prolonging properties of IDH1
MT .
Materials and Methods
Cell lines HCT116 IDH1 WT/R132H knock-in cells, generated by AAV targeting technology GENESIS (28), were kindly provided by Horizon Discovery Ltd. HT1080 chondrosarcoma cells were a kind gift of Dr. Hamann (Department of Experimental Immunology, AMC, University of Amsterdam). U251 and LN229 glioblastoma cells were stably transduced using lentiviral constructs encoding for IDH1
WT or IDH1 R132H as described earlier (29) . Constructs contain a C-terminal biotin acceptor peptide and a HIS-tag, which allows distinction from endogenous IDH1
WT by molecular weight. IDH1
WT and IDH1 R132H expression was analyzed by Western blotting using a pan-IDH1 antibody (HPA0352428, Sigma-Aldrich) and a specific antibody recognizing IDH1 R132H (30) . Western blots were analyzed using a Li-Cor Odyssey system (Li-Cor Biotechnology). lDH1 WT/R132H and lDH1 WT/WT HCT116 cells were cultured in McCoy's 5A medium (Gibco; Life Technologies; Thermo Fisher Scientific) in 5% CO 2 at 37 C. U251, LN229, and HT1080 cells were cultured in 5% CO 2 , 5% CO 2 , and 10% CO 2 , respectively, at 37 C in complete DMEM (Gibco). All media were supplemented with 10% FBS (HyClone; Thermo Fisher Scientific), 100 units/mL penicillin, and 100 mg/mL streptomycin (both Gibco).
Reagents
AGI-5198 was purchased from MedChemExpress; L-2HG, D-2HG, aKG, coenzyme A, thiamine pyrophosphate, and N-acetyl cysteine (NAC) were purchased from Sigma-Aldrich. Metformin was purchased from BioConnect.
Enzyme activity measurements
Cells were cultured in the presence of 200 to 800 nmol/L AGI-5198 or solvent only (DMSO, final concentration 0.5%) and subsequently trypsinized and centrifuged onto microscopy slides using a cytocentrifuge (Cytospin 4 Cytocentrifuge, Shandon, Thermo Fisher Scientific) at 20 rcf for 5 minutes at room temperature. Cytospins were air-dried for 1 day and subsequently stained using metabolic mapping to visualize NAD We used supraphysiological substrate concentrations (up to 30 mmol/L) because the viscous 18% polyvinyl alcohol-containing enzyme reaction medium does not allow sufficient substrate diffusion at low concentrations. Thus, the determined enzyme activities do not reflect the in vivo situation at a given substrate concentration but are suitable for intraexperimental comparisons (31) . D-2HG and L-2HG inhibition experiments were performed in the presence of 1 mmol/L isocitrate or 3 mmol/L aKG and 30 mmol/L D-2HG or 30 mmol/L L-2HG or solvent only (double-distilled H 2 O, final concentration 3%) in the enzyme activity reaction medium. The 2HG:isocitrate and 2HG:aKG ratios used in these experiments are in line with the pathophysiological conditions in human glioma where D-2HG concentrations may be up to 100-to 1,000-fold higher than isocitrate and aKG concentrations (6).
Colony-forming assays after IR
Colony-forming assays after IR were performed and analyzed as described previously (33) . Five to 500 cells/cm 2 were seeded; higher densities are needed at higher IR doses to obtain sufficient amounts of colonies. Cells were treated from 72 hours before to 4 hours after IR with D-2HG, AGI-5198, the reactive oxygen species (ROS) scavenger NAC, or solvent only (DMSO, 0.5%). Cells were irradiated with 1 to 6 Gy using a 137 Cs source (Department of Experimental Oncology and Radiobiology, Academic Medical Center, University of Amsterdam) at 6 hours after plating in the presence or absence of 0 to 800 nmol/L AGI-5198, 0 to 10 mmol/L D-2HG, or 0 to 5 mmol/L NAC. Cells were fixed and stained at 10 days after IR with a mixture of 0.05% crystal violet (Merck) and 6% glutaraldehyde (Merck) for ! 2 hours at room temperature. Clones consisting of !50 cells were manually counted using a stereoscope (Leica MZ6, Leica Microsystems; ref. 33) . Data are expressed as clonogenic fraction, 
Epigenome-wide DNA methylation analysis
Cells were lysed and genomic DNA was isolated as described previously (34) . Genomic DNA was bisulfite-converted using the EZ DNA Methylation Gold Kit (Zymo Research). Bisulfite-converted DNA was analyzed for epigenome-wide DNA methylation analysis using an Infinium HumanMethylation 450 BeadChip array (Illumina). This array includes over 450,000 CpG sites that cover approximately 99% of the RefSeq genes. Analysis was performed in the MinFI R-package (R statistical programming language), and samples were normalized using the SWAN method (35) . Normalized b-values were evaluated. Values are between 0 and 1, which stand for a completely unmethylated and methylated probe, respectively. Cellular NADP þ , NADPH, GSH, GSSG, and ROS measurements 10 6 cells were plated in a 6-well plate, incubated in the presence or absence of 800 nmol/L AGI-5198, and treated with 0 to 2 Gy IR. After 60 minutes, cells were harvested, prepared, and analyzed for NADP þ /NADPH ratios, GSH/GSSG ratios, and ROS levels using a colorimetric NADP þ /NADPH Ratio Detection Assay Kit (Abcam), a fluorometric GSH/GSSG Ratio Detection Assay Kit (Abcam), and a fluorometric CellROX Deep Red ROS detection assay kit (Life Technologies), respectively, in a 96-well plate using a POLARStar Galaxy microplate reader (BMG Labtech) according to the manufacturers' protocols. In addition, cells were analyzed for ROS levels using a CellROX Deep Red ROS detection assay kit (Life Technologies) in an LSR Fortessa fluorescence flow cytometry analyzer (BD Biosciences) according to the manufacturer's protocol. Cells were counterstained using a SYTOX Blue Dead Cell Stain (Life Technologies). Data were processed in FACSDiva (BD Biosciences) and analyzed in FlowJo (FlowJo).
g-H2AX immunofluorescence staining and measurements
DNA double-strand breaks (DSB) kinetics were studied using g-H2AX foci immunofluorescence staining (36) . Cells were plated on glass coverslips in a 6-well plate, incubated in the presence or absence of 800 nmol/L AGI-5198, and treated with 0 to 2 Gy IR, washed with PBS and fixed after 30 minutes using 2% paraformaldehyde for 15 minutes. Cells were permeabilized with pTNBS (PBS containing 1% Triton X-100 and 1% FCS) for 1 hour and stained for g-H2AX foci using a mouse monoclonal anti-g-H2AX antibody [Millipore; diluted 1:100 in sTNBS (PBS containing 0.1% Triton X-100 and 1% FCS)] for 90 min at room temperature. Cover slips were washed with sTNBS and stained using secondary goat anti-mouse Cy3 antibody (Jackson ImmunoResearch, diluted 1:100 in sTNBS) for 30 minutes at room temperature in the dark. Lastly, cover slips were washed with sTNBS, and nuclei were stained with DAPI (Millipore, 1:500) for 2 minutes at room temperature. Cover slips were mounted to microscopy slides using Vectashield (Vector Laboratories). Nail polish was used as sealant.
The number of g-H2AX foci per cell was determined using a Leica DM RA HC fluorescence microscope equipped with a CCD camera and a 100Â objective Plan Apochromatic lens with 1.40 numerical aperture (Leica Microsystems). Cy3 and DAPI signals were captured using excitation/emission wavelengths of 550/570 nm for 400 ms and 360/460 nm for 50 ms, respectively. Photomicrographs were obtained using custom-made software (Van Leeuwenhoek Center for Advanced Microscopy, Academic Medical Center, Amsterdam, the Netherlands). Stack images of at least 200 cells per sample were taken. One stack consisted of 40 slices with a 300-nm interval between the slices along the z-axis. The images were processed using deconvolution software, and the number of g-H2AX foci per cell was automatically scored using custom-made software.
Statistical analysis
Data were processed in Excel (Microsoft) and analyzed using SPSS (IBM) and GraphPad Prism 6 (GraphPad Software). Nonlinear least squares were used to fit enzyme models. Data shown are representative of, or mean AE SEM of, at least three independent experiments. P values were calculated as described in the Materials and Methods section and figure legends; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001; ÃÃÃÃ , P < 0.0001.
Results

IDH1
MT cells reduce IDH-mediated NADPH production and IR tolerance in vitro NADP þ -dependent IDH activity was significantly lower in lDH1 WT/R132H HCT116 cells than in lDH1 WT/WT HCT116 cells ( Fig. 1A; Supplementary Fig. S1A ). The reduced IDH-mediated NADPH production capacity of IDH1
MT cells was confirmed in U251 and LN229 glioblastoma cell lines that stably overexpressed IDH1 WT or IDH1 R132H (Fig. 1B-D Fig. S1B ).
IDH MT induce CIMP after long-term passaging of cells (9) . CIMP has profound effects on gene expression and, theoretically, this could alter IR sensitivity. We compared genome-wide methylation levels in early-passage (P3) and late-passage (P30) lDH1
WT HCT116 cells were exposed to D-2HG from 4 hours before to 4 hours after IR treatment. D-2HG significantly decreased the clonogenic fractions of lDH1 WT/WT and lDH1 WT/R132H HCT116 cells after IR ( Fig. 2A) , i.e., D-2HG radiosensitizes HCT116 cells. Of note, the radiosensitizing effect of D-2HG was larger in lDH1 WT/WT than in lDH1 WT/R132H HCT116 cells, in line with preexisting endogenous D-2HG in lDH1
WT/R132H HCT116 cells. D-2HG and L-2HG are competitive inhibitors of aKG-dependent enzymes (7, 8, 41) . The structural similarity between isocitrate, aKG, and D-2HG led us to hypothesize that high levels of D-2HG in IDH MT cancers inhibit IDH-mediated NADPH production capacity. To study this, we performed enzyme activity experiments in the presence and absence of D-2HG or L-2HG. D-2HG and L-2HG reduced the IDH-mediated NADPH production capacity in lDH1 WT/WT and lDH1 WT/R132H HCT116 cells, U251 glioblastoma cells, and IDH1
WT and IDH1 MT human glioblastoma tissue (n ¼ 8; Fig. 2B-E) ; this inhibition was dose-dependent ( Supplementary Fig. S2A ). In addition, D-2HG and L-2HG inhibited the aKGDH-mediated NADH production capacity in IDH1
WT and IDH1 MT human glioblastoma tissue (n ¼ 8; Fig.  2E and F) . For both IDH and aKGDH, L-2HG was a more efficient IDH inhibitor than D-2HG. These results indicate that D-2HG and L-2HG are inhibitors of IDH-mediated NADPH production capacity. D-2HG and L-2HG did not affect G6PD-mediated NADPH production capacity or IDH-dependent NADH production capacity, indicating absence of off-target effects ( Supplementary Fig. S2B and S2C ).
The IDH1
MT inhibitor AGI-5198 restores IDH-mediated NADPH production in IDH1
MT cells Since the introduction of IDH1 R132H increases metabolic stress via a reduced NADPH production capacity, we hypothesized that IDH1 R132H inhibition reverses this effect. Indeed, after 72 hours of incubation in the presence of AGI-5198, IDH-mediated NADPH production capacity of lDH1 WT/R132H HCT116 cells was restored to levels comparable with those of lDH1 WT/WT HCT116 cells (Fig.  3A) . In contrast, no effect was detected after 4 hours of incubation with AGI-5198 (Fig. 3B ) or in lDH1
WT/R132H HCT116 cells that were treated with AGI-5198 after adherence to microscopical slides ( Supplementary Fig. S3A ). This suggests that AGI-5198 restores IDH-mediated NADPH production capacity after relieving IDH1
WT/R132H cells of high D-2HG concentrations. We validated these results in IDH1 R132H U251 and LN229 cells (Fig. 3C  and D Fig. 1B; Supplementary Fig. S1C ). Larger amounts of IDH1 R132H protein may require higher AGI-5198 doses for complete IDH1 R132H inhibition. There was no effect after 72-hour incubation with AGI-5198 on NADP Fig. S3C and S3D ).
IDH1
MT cells decrease NADPH and GSH levels and increase ROS levels and AGI-5198 attenuates this effect
We investigated the effects of IDH1 MT on cellular NADPH, GSH, and ROS levels with and without pretreatment with IR. Under steady-state conditions, lDH1
WT/R132H HCT116 cells had similar NADP þ /NADPH ratios, GSH/GSSG ratios, and ROS levels as lDH1
WT/WT HCT116 cells, as determined by colorimetric and fluorometric assays and fluorescence flow cytometry experiments ( Fig. 4A-D; Supplementary Fig. S4 ). After treatment with 2 Gy IR, we observed an increase in the NADP þ /NADPH ratio (owing to more NADP þ and/or less NADPH), a decrease in the GSH/GSSG ratio (owing to less GSH and/or more GSSG), and an increase in ROS levels in all cell lines. Notably, the increase in the NADP þ / NADPH ratio and ROS levels and the decrease in the GSH/GSSG ratio were larger in lDH1 WT/R132H than in lDH1 WT/WT HCT116 cells, and the IDH1 MT inhibitor AGI-5198 attenuated this effect in lDH1 WT/R132H HCT116 cells ( Fig. 4C and D) . These findings suggest that compared with lDH1 WT/WT HCT116 cells, the higher ROS levels in lDH1 WT/R132H HCT116 cells after IR result in a higher GSH and NADPH consumption.
AGI-5198 protects IDH1
MT cells against IR Because reduced NADPH production capacity in lDH1 WT/R132H cells is associated with radiosensitization ( Fig. 1) , we hypothesized that by restoring NADPH production capacity in lDH1 MT cells, the lDH1
MT inhibitor AGI-5198 radioprotects IDH1 MT cells. Therefore, we exposed lDH1 WT/R132H and lDH1 WT/WT HCT116 cells to AGI-5198 for 72 hours before IR. AGI-5198 did not affect radiosensitivity of lDH1 WT/WT HCT116 cells, but reduced radiosensitivity of lDH1 WT/R132H HCT116 cells, in a dose-dependent fashion, to radiosensitivity levels comparable with those of lDH1 WT/WT HCT116 cells ( Fig. 5A and B) . These data show that AGI-5198 radioprotects lDH1 WT/R132H HCT116 cells and that high AGI-5198 doses completely block IDH1 R132H -induced radiosensitivity. We confirmed these findings in IDH1 R132H -overexpressing U251 glioblastoma cells (Fig. 5C) , where higher AGI-5198 doses were needed to reach a maximal effect. This is in agreement with our finding that higher AGI-5198 doses were needed to restore the IDH-mediated NADPH production capacity in U251 cells than in HCT116 cells (Fig 3A and C) . No effect on radiosensitivity of lDH1 WT/R132H HCT116 cells was observed after 4 hours of incubation with AGI-5198 (Fig. 5D ). AGI-5198 was unable to radioprotect lDH1 WT/R132H or lDH1 WT/WT HCT116 cells in the presence of D-2HG (Fig. 5E) , so the radioprotective mechanism of AGI-5198 on lDH1 WT/R132H HCT116 cells depends predominantly on the inhibition of IDH1 R132H -mediated D-2HG production.
IDH1
MT cells increase numbers of DNA DSBs and AGI-5198 reverses this effect DNA DSBs are important mediators of IR-induced cell death (36) . We therefore hypothesized that IDH1
MT cells are radiosensitized because they have increased numbers of DNA DSBs after IR. lDH1 WT/R132H HCT116 cells had more g-H2AX foci after treatment , but not in lDH1 WT/WT HCT116 cells ( Fig. 6A and B) .
MT cells increase sensitivity to metformin and AGI-5198 protects IDH1
MT cells against metformin We wondered whether the increased sensitivity of lDH1 WT/R132H HCT116 cells was specific to IR or also applicable to other treatment modalities that induce stress. IDH1
MT cells are sensitized to antidiabetic biguanides such as metformin (42, 43) , which also depend on oxidative stress to induce cell death (44 
Discussion
We showed that introduction of IDH1 R132H results in D-2HG accumulation, inhibits IDH WT function, and sensitizes cells to IR and metformin. The overall process can thus be described as a D-2HG-NADPH-therapy sensitivity cascade for IDH1
MT cancer cells (Fig. 7) . Inhibition of IDH1
MT by AGI-5198 disrupts this cascade at the level of D-2HG production, which enhances the capacity of IDH1
MT cells to reduce oxidative stress and protects them against IR and metformin.
Patients with glioma or cholangiocarcinoma tumors carrying IDH MT have prolonged overall survival compared with IDH WT counterparts (3, 5, 10, 11) . This can be attributed to intrinsic (e.g., less aggressive tumors) and/or extrinsic (e.g., better response to therapy) differences in IDH MT versus IDH WT cancers. Our data support a correlation between IDH MT and response to therapy, 
IDH1
MT decrease NADPH levels and GSH levels, increase ROS levels, and AGI-5198 attenuates this effect. A, cells were incubated in the presence or absence of 800 nmol/L AGI-5198 and treated with 0 to 2 Gy IR and were harvested, prepared, and colorimetrically analyzed for NADP þ /NADPH ratios after 60 minutes. B, as in A, but with fluorometric analysis for GSH/GSSG ratios. C, as in A, but with fluorometric analysis for ROS levels. D, as in C, but with fluorescence-guided flow cytometry analysis for ROS levels (x-axis) and viable cells (y-axis). P values were obtained using one-way ANOVA on the difference between IR-treated and untreated cells using Tukey correction for multiple comparisons. All concentrations in the figure refer to AGI-5198. Research.
on April 14, 2017. © 2015 American Association for Cancer cancerres.aacrjournals.org Downloaded from which has been shown by others, both in vitro (15) (16) (17) and retrospectively in the clinic (18, 19) . Our novel finding is that D-2HG accumulation, as occurs in IDH1
MT cancers, directly radiosensitizes cancer cells via inhibition of IDH-mediated NADPH production capacity and that this is associated with increased numbers of DNA DSBs after IR. Thus, the prolonged survival effects of IDH MT in glioma patients may, at least partly, be the result of a relative radiosensitivity of IDH1 MT cancer cells.
IDH
MT confer a worse prognosis in AML patients (45) . One difference between AML and glioma is that IR is typically not used to treat AML, whereas it is routinely used as a treatment modality for glioma. Cytarabine and daunorubicin are used to treat AML and operate by DNA synthesis chain termination and topoisomerase activity, which cause cell death independent of ROS formation. Furthermore, D-2HG accumulation in AML cells has likely less biologic impact since NADPH production in leukocytes is largely attributable to activity of G6PD, not IDH1/2 (46) . In contrast, IDH1/2 is responsible for 65% of NADPH production in glioblastoma, and IDH1
MT decrease NADPH production capacity by 38% (5), making these tumors dependent on IDH1/2 for reducing power.
In addition to glioblastoma and chondrosarcoma cell lines, we used HCT116 colorectal carcinoma cells as in vitro model. Although IDH1
MT are not as prevalent in colorectal carcinoma as in glioma, chondrosarcoma, or cholangiocarcinoma, they do occur in 0.5% of patients (47 HCT116 cells is more true to nature than IDH1 R132H overexpression. Previous reports (3, 5) have shown that the loss-of-function effects of IDH1
MT are responsible for reduced IDH-mediated NADPH production capacity in IDH1
MT tumors. In cancer cells, IDH1 R132H mutations are heterozygous, i.e., cells lose one functional NADPH-producing allele. In addition, the net NADPH production in IDH1
MT cells is further reduced via NADPH consumption by IDH1 R132H (6) . However, reductive hydroxylation of aKG by IDH1 R132H occurs 100 to 1,000 times slower than the oxidative decarboxylation by IDH WT (6, 48) , so such compounding is likely negligible. The present study shows that IDH1
MT reduce NADPH production capacity through a third mechanism: IDH1 R132H -produced D-2HG inhibits IDH WT . This supports earlier findings that IDH1 MT inhibit catalytic IDH1 WT function in a dominant-negative fashion (4) . We show that this dominantnegative inhibition is mediated by D-2HG. Another, but not mutually exclusive, explanation is that this dominant-negative inhibition is mediated by dysfunctional IDH1 WT/R132H HCT116 cells. Of note, L-2HG was a more potent inhibitor than D-2HG of IDH and aKGDH. This corroborates studies that showed that L-2HG is a more potent inhibitor than D-2HG of aKG-dependent enzymes, such as TET2, JHKDMs, and EGLN (7, 8) .
AGI-5198 restored IDH-mediated NADPH production capacity and radioresistance of IDH1
MT cells, and both effects are likely the result of AGI-5198-inhibited D-2HG synthesis. High-dose AGI-5198 completely abolishes D-2HG accumulation (23) MT cells against metformin. This is in agreement with the fact that mitochondrial inhibitors such as metformin depend on oxidative stress to induce cell death (44) . Previous reports have shown that D-2HG induces cellular oxidative stress (37) (38) (39) (40) , although the underlying mechanisms remained elusive thus far. Our data indicate that inhibition of IDH-mediated NADPH production capacity and aKGDH-mediated NADH production capacity by D-2HG and the resulting metabolic stress is, at least partly, responsible for this phenomenon. Our findings that D-2HG and L-2HG inhibit the activity of IDH WT and aKGDH suggest that this inhibition is due to the chemical similarities between D-2HG, L-2HG, and aKG.
Long-lasting exposures of AGI-5198 (72 hours) radioprotected IDH1
MT cells but short exposures (4 hours) did not. These data corroborate our quantitative enzyme histochemistry results where 72-hour exposure to high doses of AGI-5198 completely restored IDH-mediated NADPH production capacity of lDH1
MT cells, but 4-hour exposures did not. This indicates that there is a delaying MT decreased NADPH and GSH levels and increased ROS in glioblastoma cells after treatment with temozolomide and CDDP (15), but not in a transgenic mouse model or glioblastoma cells under steady-state conditions (15, 52) . Taken together, our results suggest that in contexts of stress, such as after treatment with IR, the cellular demand for GSH increases. As a consequence, the demand for NADPH increases, but IDH1
MT compromise the cellular NADPH production capacity, and this restricts recycling of GSSG to GSH enough to cause higher ROS levels, i.e., it causes a scenario in which NADPH demand outweighs NADPH supply. In all, our results suggest that altered oxidative stress response is the most likely downstream element of causing mitochondrial ROS (54) . In addition, other Achilles' heels in IDH MT metabolism could be exploited, such as mitochondrial dysfunction (50) , increased dependence on glutaminolysis (2, (55) (56) (57) (58) (59) and oxidative phosphorylation (42, 43) . These vulnerabilities can be pharmacologically targeted via BCL-2 inhibitors, chloroquine, and metformin, respectively.
In summary, our data show that AGI-5198 radioprotects IDH1
MT cancer cells. Administration of IDH MT inhibitors during IR may thus abolish the prolonged survival of IDH MT glioma patients. We warn against multiagent clinical trials with concomitant use of IDH MT inhibitors and IR.
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